Indeed, nuclear AXL ICD was detected in pancreatic and lung cancer cells treated with the proteasome inhibitor, suggesting that two competing mechanisms, nuclear import and proteasome-dependent degradation, define AXL ICD fate [99]. This evidence concerns the gene AXL and lung cancer.